H.C. Wainwright raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $20 from $18 and keeps a Buy rating on the shares. The firm added imsidolimab to its valuation assessment. Vanda’s “ambitious” long-term revenue goals look achievable, even without some late-stage assets, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals’ Earnings Call: Mixed Results and Future Optimism
- Vanda Pharmaceuticals Sees Revenue Growth Amid Strategic Expansions
- Vanda Pharmaceuticals sees FY25 revenue $210M-$250M, consensus $284.9M
- Vanda Pharmaceuticals targets total annual revenue in excess of $1B in 2030
- Vanda Pharmaceuticals reports Q EPS (8c) vs. (4c) last year